Response to the Letter to the Editor: "Pyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine"

被引：1
|
作者：
Marques dos Santos, Carlos Henrique [1 ]
Koga, Gabrielli Avelar [2 ]
机构：
[1] Anhanguera UNIDERP Univ, Campo Grande, MS, Brazil
[2] Reg Hosp Mato Grosso Sul, Campo Grande, MS, Brazil
来源：
INFLAMMATORY BOWEL DISEASES | 2021年 / 27卷 / 10期
关键词：
D O I：
10.1093/ibd/izab107
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E118 / E118
页数：1
相关论文
共 34 条
  • [31] An older patient with active ulcerative colitis and coronavirus disease 2019 (COVID-19) pneumonia successfully treated with the combination of anti-TNFα therapy and azathioprine
    Yamakawa, Tsukasa
    Ishigami, Keisuke
    Ohwada, Sae
    Kazama, Tomoe
    Hirayama, Daisuke
    Yoshii, Shinji
    Yamano, Hiro-O
    Nakase, Hiroshi
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2023, 16 (02) : 187 - 192
  • [32] Adalimumab-Receiving Ulcerative Colitis Patient Suffered Latent Tuberculosis Reactivation Despite Correct Chemoprophylaxis and was Successfully Treated while on Anti-Tumour Necrosis Factor Therapy
    Agudo, Belen
    Diaz, Gema
    Gonzalez-Lama, Yago
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (12): : 1453 - 1454
  • [33] Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies
    D'Haens, Geert
    Baert, Filip
    Danese, Silvio
    Kobayashi, Taku
    Loftus, Edward V.
    Sandborn, William J.
    Dornic, Quentin
    Lindner, Dirk
    Kisfalvi, Krisztina
    Marins, Ed G.
    Vermeire, Severine
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (04) : 404 - 415
  • [34] Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
    Abdullah, Abdullah
    Neurath, Markus F.
    Atreya, Raja
    VISCERAL MEDICINE, 2020, 36 (04) : 338 - 342
1234